by Sheri Colberg, Ph.D., FACSM
My last article focused on why glucose was the best short-term treatment for hypoglycemia, but this time I want to switch gears and talk about why treating lows is not as straight-forward as you would think. It mainly stems from the fact that sometimes hypoglycemia can be very difficult to treat effectively and even hard to prevent in many cases, particularly related to physical activity.

What physiological feature puts East Asians at increased risk for type 2 diabetes? 1. Greater insulin resistance 2. Lower levels of endogenous incretins 3. Increased beta-cell dysfunction 4. Increased incidence of dyslipidemias Did you get it right? Follow the link to see the correct answer!

What percentage of your patients have a difficult time following their diabetes treatment regimen? 1) Greater than 75% 2) Greater than 50% 3) Less than 50% 4) Less than 25% Follow the link to share your opinion!

This morning I was listening to my local NPR station, and although they don’t have advertising like a regular station, they do have sponsors. One sponsor, a major vitamin and nutrition company, was making a big deal about new products and new programs for the new year. I knew that …

Yes, it’s that time of year again when your phone/email/computer is busy with patients wanting appointments and making commitments to make their New Year’s Resolutions. Often at this time of the year, my patients come in wanting to change just about everything about what they eat, when they eat, how much they eat, and the same for being physically active. So many of these patients have told me they have tried and tried and tried and failed in the past, but now it’s the New Year and it’s going to be different.

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 9 of this Exclusive Interview, Dr. Mechanick reiterates his call for the individualization of diabetes care.

In this week's Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.

Potential mechanisms of incretin dysfunction in type 2 diabetes: Various potential explanations have been expounded in order to explain the reduced incretin effect in type 2 diabetes. One obvious factor to examine was the secretion of GIP and GLP-1. Regarding GIP, a number of studies have compared postprandial plasma concentrations between patients with and without diabetes. These studies have revealed increased, normal, or reduced GIP levels in patients with diabetes. Considering all studies together, there does not appear to be a general defect in GIP secretion. If anything, a slight increase in postprandial GIP levels might occur in patients with early type 2 diabetes, but clearly the differences in GIP levels would not sufficiently explain any alterations in insulin of glucose concentrations.

To view this video in full, click here. Steve Freed: Maybe start off by telling us a little bit about yourself because you have an interesting background. Dr. Mechanick: I’m a clinical endocrinologist in private practice in New York City and an attending and clinical professor at Mount Sinai, at the Icon …

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting about the role of nutrition and lifestyle as a preventative method in treating diabetes. Dr. Jeffrey Mechanick, MD, FACP, FACE, FNLA is the Clinical Professor of Medicine and Director of Metabolic Support in the …